quality, safety, and efficacy of products for the final approval by the CHMP. Furthermore, the committee should be consulted for the evaluation of other products under its competence. ###>Amendement 37 ARTICLE 23, POINT a bis) (nouveau) (a bis) donner un avis, conformément à l'article 18, sur le point de savoir si un médicament relève de la définition du médicament de thérapie innovante.